Protagonist Therapeutics, Inc. $PTGX Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 62.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,400 shares of the company’s stock after purchasing an additional 9,800 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Protagonist Therapeutics were worth $2,218,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after purchasing an additional 314 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics during the third quarter valued at $62,000. Osaic Holdings Inc. lifted its holdings in shares of Protagonist Therapeutics by 79.5% during the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after purchasing an additional 525 shares during the last quarter. Finally, Canton Hathaway LLC purchased a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at $87,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Trading Down 3.2%

NASDAQ:PTGX opened at $102.18 on Friday. The firm has a market capitalization of $6.57 billion, a price-to-earnings ratio of -56.45 and a beta of 1.89. Protagonist Therapeutics, Inc. has a 1-year low of $44.04 and a 1-year high of $107.84. The business’s fifty day moving average price is $100.73 and its 200 day moving average price is $90.47.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The company had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current year.

Insider Buying and Selling

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the transaction, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at $52,410,617.36. This represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bryan Giraudo sold 36,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $100.14, for a total value of $3,605,040.00. Following the completion of the transaction, the director directly owned 27,825 shares in the company, valued at approximately $2,786,395.50. The trade was a 56.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 272,345 shares of company stock worth $27,294,066. Insiders own 5.19% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on PTGX. Truist Financial upped their target price on Protagonist Therapeutics from $110.00 to $121.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. JPMorgan Chase & Co. upped their target price on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Leerink Partners upped their price target on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. HC Wainwright upped their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Wedbush upped their price target on Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $113.69.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.